TransMedics Group (NASDAQ:TMDX) Given New $110.00 Price Target at Needham & Company LLC

TransMedics Group (NASDAQ:TMDX) had its price target increased by equities researchers at Needham & Company LLC from $106.00 to $110.00 in a report released on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC‘s price target suggests a potential upside of 25.80% from the stock’s previous close.

Other analysts have also issued reports about the company. Zacks Research raised TransMedics Group from a “strong sell” rating to a “hold” rating in a research note on Monday. TD Cowen reaffirmed a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a research note on Tuesday, September 8th. Piper Sandler reiterated an “overweight” rating and issued a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Barclays started coverage on shares of TransMedics Group in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 target price on the stock. Finally, Weiss Ratings raised shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Five equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $118.60.

TransMedics Group Price Performance

Shares of TMDX traded up $18.46 during trading hours on Friday, reaching $87.44. The stock had a trading volume of 1,980,634 shares, compared to its average volume of 1,010,329. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The stock has a market capitalization of $3.02 billion, a PE ratio of 22.29, a PEG ratio of 1.00 and a beta of 2.14. The company’s 50-day moving average is $79.68 and its two-hundred day moving average is $93.44.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.30 by $0.21. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The business had revenue of $203.01 million for the quarter, compared to analyst estimates of $178.06 million. During the same quarter in the previous year, the company posted $0.66 EPS. TransMedics Group’s quarterly revenue was up 41.1% compared to the same quarter last year. Research analysts expect that TransMedics Group will post 1.46 EPS for the current year.

Insider Activity at TransMedics Group

In related news, Director David Weill purchased 1,336 shares of TransMedics Group stock in a transaction on Friday, September 11th. The shares were purchased at an average price of $81.63 per share, for a total transaction of $109,057.68. Following the transaction, the director owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. This represents a 8.87% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently made changes to their positions in TMDX. Braidwell LP increased its position in TransMedics Group by 85.1% during the 2nd quarter. Braidwell LP now owns 609,715 shares of the company’s stock valued at $40,497,000 after purchasing an additional 280,324 shares during the period. Deutsche Bank AG acquired a new position in shares of TransMedics Group in the 2nd quarter worth approximately $14,415,000. Bank of New York Mellon Corp acquired a new position in shares of TransMedics Group in the 2nd quarter worth approximately $12,869,000. Trek Financial LLC bought a new stake in shares of TransMedics Group in the 3rd quarter valued at $11,989,000. Finally, Legal & General Group Plc bought a new stake in shares of TransMedics Group in the 2nd quarter valued at $5,286,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting TransMedics Group

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Third-quarter revenue rose 41.1% year over year to $203 million, exceeding the roughly $178 million analyst estimate. Adjusted earnings were $0.51 per share, also above consensus. TransMedics third-quarter results
• Positive Sentiment: TransMedics raised its 2026 revenue guidance to $764 million–$774 million, signaling confidence in continued growth. Revenue guidance and catalysts
• Neutral Sentiment: Unusual options activity was reported after earnings, but the article does not indicate whether trading was bullish or bearish. Unusual options volume report
• Negative Sentiment: Despite beating estimates, quarterly EPS declined from $0.66 a year earlier to $0.51. The company also pushed the ENHANCE Part B and DENOVO catalysts to early 2027, potentially delaying related updates. Revenue guidance and catalysts

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.